regulatory sciences

Regulatory Sciences applies scientific principles to ensure products meet safety, efficacy, and compliance standards across global markets. This discipline plays a critical role in bringing new therapies to patients while adhering to evolving regulatory requirements. The blog posts below explore how regulatory science supports innovation and approval processes.
Pharma omnichannel marketing hand on tablet

Regulatory Sciences

Omnichannel Marketing in Pharma: A Strategy Guide for Regulatory Compliance

As emerging marketing technologies rapidly evolve and reach maturity, marketers can now unlock sophisticated new tools to more efficiently and effectively reach consumers. As always, marketers remain...

Regulatory Sciences

Mastering Clinical Trial Submissions in Europe: A Guide for Drug Developers

Launching a clinical trial in Europe is a complex but rewarding endeavor, requiring careful navigation of regulatory frameworks, ethical requirements, and submission processes. Recent regulatory...

Technology transfer documents floating

Regulatory Sciences

CMC Expectations During Drug Substance Transfer from Ex-US Manufacturers

Regulatory Drivers for US-based API Manufacturers Recent shifts in US tariff policies have introduced new pressure points in the global pharmaceutical supply chain, particularly for manufacturers...

European union eu flags flying in front of building

Regulatory Sciences

Advancing Digital Transformation in Medicines: EMA's Successful ePI Pilot

The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) have recently concluded a successful pilot project on electronic product information (ePI), marking a significant...

Large pile of documents and files on an office desk

Regulatory Sciences

FDA's "Radical Transparency" Shift: What Regulatory Pros Need to Know

A New Era of FDA Disclosure On Thursday, July 10, 2025, FDA published more than 200 decision letters, known as complete response letters (CRLs). The CRLs were issued in response to applications...

Regulatory Sciences

Leveraging Online FDA Information to Accelerate ANDA Timelines

In the race to generic drug approval, timing is everything. Delays in Abbreviated New Drug Application (ANDA) submissions or setbacks during FDA review can mean missed market opportunities,...

Business professionals meeting gathered around table

Regulatory Sciences

Maximizing the Value of FDA Pre-IND Meetings for Successful 505(b)(2) NDA Submissions

For drug developers leveraging the 505(b)(2) pathway, the FDA Pre-Investigational New Drug (Pre-IND) meeting is a strategic opportunity that can shape the trajectory of an entire development program....

White pills behind magnifying glass

Regulatory Sciences

FDA's Commissioner’s National Priority Voucher (CNPV) Pilot Program Overview

An inside look at FDA's new Commissioner's National Priority Voucher (CNPV) pilot program—what it is, why it matters, and how regulatory and development teams can leverage it to accelerate...

professionals meeting at conference table to discuss fda submission for medical device

Regulatory Sciences

Navigating FDA's Q-Submission Process: A Strategic Advantage for Medical Device Developers

In the highly regulated medical device industry, navigating FDA's submission process can be daunting, especially for start-ups. However, FDA's Q-Submission (Q-Sub) program offers a valuable...

Person wearing protective equipment reviewing a tablet device

Quality & Compliance

15 Days of Panic Revisited: You Received an FDA Form or 483 Form Warning Letter, Now What?

Remember the last time you were pulled over by law enforcement? Maybe it was for a broken taillight or driving a few miles over the speed limit. Even if you believed you hadn't done anything wrong,...

1 2 3 4 5